Search

Search Constraints

You searched for: Author/Creator Sebag, Michael

Search Results

1. A Covalent Cysteine‐Targeting Kinase Inhibitor of Ire1 Permits Allosteric Control of Endoribonuclease Activity. (7th March 2016)

2. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial. Issue 6 (June 2022)

3. Carfilzomib usage patterns and outcomes in patients with relapsed multiple myeloma: A multi‐institutional report from the Canadian Myeloma Research Group (CMRG) Database. Issue 4 (31st August 2022)

4. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Issue 10027 (9th April 2016)

5. Outcomes of daratumumab in the treatment of multiple myeloma: A retrospective cohort study from the Canadian Myeloma Research Group Database. (5th April 2022)

6. Pomalidomide plus low‐dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure. (6th October 2019)

7. Pomalidomide, dexamethasone, and daratumumab immediately after lenalidomide-based treatment in patients with multiple myeloma: updated efficacy, safety, and health-related quality of life results from the phase 2 MM-014 trial. Issue 6 (12th May 2022)

9. Real‐world data on lenalidomide dosing and outcomes in patients newly diagnosed with multiple myeloma: Results from the Canadian Myeloma Research Group Database. (26th September 2022)

10. Real‐world outcomes with bortezomib‐containing regimens and lenalidomide plus dexamethasone for the treatment of transplant‐ineligible multiple myeloma: a multi‐institutional report from the Canadian Myeloma Research Group database. (9th February 2021)